(Q38494130)

3 September 2017

title

Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix (English)

1 reference

3 September 2017

Myong Cheol Lim

2

0 references

Sokbom Kang

object named as

Sokbom Kang

5

0 references

author name string

Jong Ha Hwang

1

1 reference

3 September 2017

Sang-Soo Seo

3

1 reference

3 September 2017

Sang-Yoon Park

4

1 reference

3 September 2017

publication date

24 February 2011

1 reference

Japanese Journal of Clinical Oncology

3 September 2017

published in

1 reference

3 September 2017

volume

41

1 reference

3 September 2017

issue

5

1 reference

3 September 2017

page(s)

624-629

1 reference

Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR017

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR017

A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR017

A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR017

Review role of topotecan in gynaecological cancers: current indications and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR017

In vitro pharmacodynamics of CKD-602 in HT-29 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR017

Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR017

A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR017

Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR017

Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR017

Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR017

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYR017

1 reference

3 September 2017

1 reference